In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
PR Newswire
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
BioSpace
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AITHORITY
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
BioMed X Launches New T Cell Immunology Discovery Platform
GlobeNewswire
The underlying technology emerged from a collaboration between BioMed X and Janssen Research & Development, LLC (Janssen). An international team of outstanding early-career researchers was recruited through the unique BioMed X crowdsourcing model. During a five-year research project at the BioMed X Institute in Heidelberg, the team developed a new platform technology for “Rapid Identification of Auto-Antigens in Autoimmune Diseases.”
BioMed X Launches New T Cell Immunology Discovery Platform
FinanzNachrichten
BioMed X announced today the launch of its new immunology discovery platform that will allow for the accurate and fast identification of target antigens of human T cell receptors (TCRs). The research team led by John Lindner, who has developed the new technology, is based at the BioMed X Institute in Heidelberg, Germany.
BioMed X to establish first US-based research institute in New Haven
New Haven Biz
BioMed X, a biomedical research institute in Germany, is launching its first U.S. facility here in New Haven. The BioMed X Institute in New Haven will focus on research in the areas of immunology and tissue engineering.
German Biomed Researchers Pick New Haven For U.S. Post
New Haven Independent
A German biomedical research institute is putting down roots in New Haven, with newly announced plans to move into a local lab space later this year as it partners with a biopharmaceutical company to study immunology and tissue engineering. That research firm is called BioMed X.
BioMed X Extends Research Collaboration With AbbVie On Immunology And Tissue Engineering
RTT News/Nasdaq
BioMed X noted that the new US-based research collaboration will focus on immunology and tissue engineering, following a first joint research project on Alzheimer’s disease at the BioMed X Institute in Heidelberg, Germany.
BioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie
BioSpace
“Extending our successful partnership with AbbVie to our new site in the US is a big milestone for our institute,” said Christian Tidona, Founder and Managing Director of BioMed X.